TITLE

FDA Actions

PUB. DATE
September 2007
SOURCE
Travel Medicine Advisor;Sep2007, Vol. 17 Issue 9, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information on drugs approved by the FDA. The Oncologic Drugs Advisory Committee of the FDA has recommended the approval of raloxifene for the prevention of breast cancer in high risk women. Restricted use of tegaserod for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation was accredited by the agency. The FDA has advised that rosiglitazone stay on the market despite its link with an increased heart failure and myocardial infarction.
ACCESSION #
26599678

 

Related Articles

  • FDA Actions. Elliott, William T. // OB/GYN Clinical Alert;Sep2007, Vol. 24 Issue 5, p2 

    The article presents an update on drugs approved by the U.S. Food and Drug Administration (FDA) as of September 2007. Its Oncologic Drugs Advisory Committee has recommended the approval of raloxifene for the prevention of breast cancer in high risk women. It has approved the restricted use of...

  • FDA Actions.  // Clinical Cardiology Alert;Sep2007, Vol. 26 Issue 9, p2 

    This section offers news briefs on drug approvals of the U.S. Food and Drug Administration (FDA). It says that the approval of raloxifene has been recommended by the Oncologic Drugs Advisory Committee for the indication of breast cancer prevention in high risk women. The restricted use of...

  • FDA actions. Elliott, William T. // Clinical Oncology Alert;Jul2008 Pharmacology Watch, p2 

    The article reports on several actions taken by the U.S. Food & Drug Administration (FDA) as of July 2008. A broad new labeling requirements had been proposed by the FDA for prescription drugs regarding their use during pregnancy and breast-feeding. The agency also approved lubiprostone for the...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Sep2007, Vol. 13 Issue 9, p2 

    The article offers news briefs related to drug approval in the U.S. The Oncologic Drugs Advisory Committee of the U.S. Food & Drug Administration (FDA) has recommended the approval of raloxifene for the indication of breast cancer prevention in high risk women. The FDA has approved restricted...

  • Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p232 

    The article reports that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) of linaclotide from Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. It notes that the drug is indicated for the management of irritable bowel syndrome with...

  • NEWSLINE: Two IBS-D Treatments Gain Approval.  // Monthly Prescribing Reference;Jul2015, Vol. 31 Issue 7, pA8 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to Viberzi from pharmaceutical company Actavis PLC and Xifaxan 550mg from Salix which are both for treatment of irritable bowel syndrome with diarrhea.

  • FDA approves two IBS drugs. Mullard, Asher // Nature Reviews Drug Discovery;Jul2015, Vol. 14 Issue 7, p449 

    The article reports on the U.S. Food and Drug Administration's approval of two drugs for irritable bowel syndrome (IBS) with diarrhoea, the eluxadoline developed by Allergan and the rifaximin from Valeant, in May 2015.

  • New Therapies for Irritable Bowel Syndrome. Voelker, Rebecca // JAMA: Journal of the American Medical Association;7/7/2015, Vol. 314 Issue 1, p17 

    The article announces the approval by the U.S. Food and Drug Administration (FDA) of the drugs eluxadoline marketed as Viberzi and rifaximin marketed as Xifaxan, for the treatment of bowel syndrome with diarrhea (IBS-D) in adults.

  • FRONT LINE.  // Women's Health Advisor;Sep2015, Vol. 19 Issue 9, p2 

    The article offers health news brief as of September 2015. Topics discussed include shorter course of higher-dose radiation showed no increase in cancer recurrence and is beneficial for breast cancer patients according to a study, drug approval of alirocumab (Praluent) by the U.S. Food and Drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics